

Micro-X Limited, ABN 21 153 273 735

25 July 2019

ASX Market Announcements Office ASX Limited Level 4, North Tower, Rialto 525 Collins Street Melbourne VIC 3000

By electronic lodgement

Dear Ms Tang,

Notice under section 708A(5)(e) of the Corporations Act 2001 (Cth)

Micro-X Limited (ASX:MX1) (ACN 153 273 735) (MX1) gives notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) (Act) that:

- (a) on the following dates MX1 issued the following securities upon conversion of unlisted convertible notes issued by MX1 on 5 October 2018:
 - (i) on 4 June 2019, 2,161,695 ordinary shares were issued at \$0.2313 per share:
 - (ii) on 14 June 2019, 2,173,913 ordinary shares were issued at \$0.23 per share; and
 - (iii) on 10 July 2019, 2,173,913 ordinary shares were issued at \$0.23 per share;
- (b) this notice is given within the time period specified by order of the Federal Court of Australia made on 25 July 2019 and is deemed to take effect as if it had been given to the ASX within 5 business days after the dates of issue of the shares specified in paragraph (a) above;
- (c) the shares referred to above were issued without disclosure under Part 6D.2 of the Act;
- (d) as at the date of this notice, MX1 has complied with:
 - (i) the provisions of Chapter 2M of the Act as they apply to MX1; and
 - (ii) section 674 of the Act as it applies to MX1; and
- (e) as at the date of this notice, there is no "excluded information" of the type referred to in sections 708A(7) and 708A(8) of the Act that is required to be set out in this notice under section 708A(6)(e) of the Act.

Yours sincerely

Georgina Carpendale Company Secretary

Micro-X Limited



About Micro-X

Micro-X Limited (the **Company**) is an ASX listed hi-tech company developing and commercialising a range of innovative products for the global health and security markets, based on proprietary cold cathode, carbon nanotube emitter technology. The electronic control of emitters with this technology enables X-ray products with significant reduction in size, weight and power requirements, enabling greater mobility and ease of use in existing x-ray markets and a range of new and unique security and defence applications. The Company has its core R&D, engineering and production capability at its facility in Adelaide, Australia.

The Company's first product, the *Carestream DRX Revolution Nano*, is an ultra-lightweight digital medical x-ray system for the rapidly expanding mobile x-ray market in hospitals and healthcare. The *Carestream DRX Revolution Nano* holds 510(k) and CE Mark certifications and is sold commercially in a number of global markets by the Company's exclusive distributor, Carestream Health, Inc.. The Company has a portfolio of innovative products in development, aimed at customer solutions where there is little or no competition. This includes the Mobile Backscatter Imager or MBI which will image Improvised Explosive Devices for security, defence and counter-terrorism applications. The MBI is being jointly developed in partnership with Thales, a global supplier of defence and security technology systems, who are providing technical support and \$10 million of funding.

CONTACTS

Micro-X Limited	Investor Enquiries
Peter Rowland	David Allen / John Granger
Managing Director	Hawkesbury Partners
Tel: +61 8 7099 3966	Tel: +61 2 9103 9494
E: admin@micro-x.com	E: dallen@hawkesburypartners.com